DxLab develops the DxHub, a standalone point-of-care molecular testing system for infectious diseases. This system utilizes isothermal nucleic acid amplification chemistry to deliver PCR-quality results in as little as 10 minutes per sample. The platform enables high-capacity, rapid, and accurate infectious disease detection without requiring sample batching.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Infectious diseases require rapid and accurate detection to minimize their spread and impact, but traditional testing methods often involve long turnaround times and high-complexity laboratories. This can lead to delays in diagnosis and treatment, hindering effective disease management and containment.
Solution
DxLab provides DxHub, a point-of-care molecular testing system designed for rapid and accurate infectious disease detection. DxHub enables on-demand testing of multiple samples without batching, delivering PCR-quality results in as little as 10 minutes. The system combines patent-pending isothermal nucleic acid amplification chemistry with machine learning-based design optimizations to develop fast, accurate, and affordable infectious disease tests. This allows for quicker turnaround times, better management of infectious diseases, and reduced waiting times for test results, even with high patient volumes.
Target Audience
The primary target audience includes healthcare providers and organizations that require rapid, accurate, and convenient infectious disease testing outside of high-complexity laboratory settings.
Features
- Standalone point-of-care molecular testing system
- Rapid turnaround time, delivering results in as little as 10 minutes
- PCR-quality accuracy for reliable test results
- High testing capacity, capable of running multiple samples on a single compact device
- Patent-pending isothermal nucleic acid amplification chemistry
- Machine learning-based design optimizations for test development
- COVID-19 test authorized by the FDA for emergency use